The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gavrilina O.A.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva

Parovichnikova E.N.

Federal state budgetary institution 'Hematological Research Centre', Russian Ministry of Health, Moscow, Russia

Zvonkov E.E.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva

Troitskaya V.V.

Federal state budgetary institution 'Hematological Research Centre', Russian Ministry of Health, Moscow, Russia

Kravchenko S.K.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii

Savchenko V.G.

National Research Center for Hematology, Moscow, Russia

Diffuse large B-cell lymphoma with monoclonal immunoglobulin secretion

Authors:

Gavrilina O.A., Parovichnikova E.N., Zvonkov E.E., Troitskaya V.V., Kravchenko S.K., Savchenko V.G.

More about the authors

Journal: Therapeutic Archive. 2016;88(7): 56‑61

DOI: 10.17116/terarkh201688756-61

Read: 4297 times

Download PDF (RU)
Contact the author
Table of contents

DIFFUSE LARGE B-CELL LYMPHOMA WITH MONOCLONAL IMMUNOGLOBULIN SECRETION
DIFFUSE LARGE B-CELL LYMPHOMA WITH MONOCLONAL IMMUNOGLOBULIN SECRETION

To cite this article:

Gavrilina OA, Parovichnikova EN, Zvonkov EE, Troitskaya VV, Kravchenko SK, Savchenko VG. Diffuse large B-cell lymphoma with monoclonal immunoglobulin secretion. Therapeutic Archive. 2016;88(7):56‑61. (In Russ.)
https://doi.org/10.17116/terarkh201688756-61

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Aim. To provide the clinical characteristics of patients with diffuse large B-cell lymphoma (DLBCL) with monoclonal immunoglobulin secretion and to evaluate the efficiency of intensified mNHL-BFM-90 or R-DA-EPOCH/R-HMA therapy programs in patients with Ig-secreting DLBCL. Subjects and methods. A clinical trial was conducted in 93 patients with newly diagnosed DLBCL, among whom 21 (22.6%) were found to have monoclonal immunoglobulin secretion. Results. Ig-secreting DLBCL is shown to be characterized by bone marrow involvement (p<0.001), as well as generalized injury (Ann Arbor Stage 4) and a high risk in accordance with the international prognostic index (p=0.001 and p=0.026, respectively). Analysis of overall and event-free survival rates has indicated that the patients have a poor prognosis versus those with non-Ig-secreting DLBCL and poor prognostic factors even when implementing intensified therapy programs, such as mNHL-BFM-90 or R-DA-EPOCH/R-HMA ones. Conclusion. The investigation has demonstrated that there is a high association of the secretion of monoclonal paraproteins with bone marrow involvement in DLBCL (p<0.001). The intensified therapy using the mNHL-BFM-90 and R-DA-EPOCH/R-HMA programs involving autologous hematopoietic stem cell transplantation also permits the patients with Ig-secreting DLBCL to achieve long-term sustained remissions in not all cases.

Keywords:

diffuse large B-cell lymphoma
monoclonal immunoglobulin secretion
intensified polychemotherapy
bone marrow involvement

Authors:

Gavrilina O.A.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva

Parovichnikova E.N.

Federal state budgetary institution 'Hematological Research Centre', Russian Ministry of Health, Moscow, Russia

Zvonkov E.E.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva

Troitskaya V.V.

Federal state budgetary institution 'Hematological Research Centre', Russian Ministry of Health, Moscow, Russia

Kravchenko S.K.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii

Savchenko V.G.

National Research Center for Hematology, Moscow, Russia

Close metadata

References:

  1. Swerdlow S, Campo E, Harris NL et al. International Agency for Research on Cancer. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Geneva, Switzerland: World Health Organization; 2008. doi:10.1002/9781118853771.ch51
  2. Shipp MA, Harrington DP, Anderson JR et al. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin’s lymphoma. New Engl J Med. 1993;329(14):987-994.  doi:10.1056/NEJM199309303291402
  3. Muller C, Murawski N, Wiesen MH et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012;119:3276-3284. doi:http://dx.doi.org/10.1182/blood-2011-09-380949
  4. Pfreundschuh M, Ho AD, Cavallin-Stahl E et al. Prognostic significance of maximum tumor (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol. 2008;9:435-444.  doi:10.1016/S1470-2045(08)70078-0
  5. Chung R, Lai R, Wei P, Lee J, Hanson J, Belch AR, Turner AR, Reiman T. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood. 2007;110(4):1278-1282. doi:http://dx.doi.org/10.1182/blood-2007-01-070300
  6. Choi WW, Weisenburger DD, Greiner TC et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15:5494-5502. doi:10.1158/1078-0432.CCR-09-0113
  7. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-282.  doi:http://dx.doi.org/10.1182/blood-2003-05-1545
  8. Aukema SM, Siebert R, Schuuring E et al. Double-hit B-cell lymphomas. Blood. 2011;117(8):2319-2331. doi:http://dx.doi.org/10.1182/blood-2010-09-297879
  9. Barrans S, Crouch S, Smith A et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28:3360-3365. doi:10.1200/JCO.2009.26.3947
  10. Johnson N, Slack G, Savage K et al. Concurrent expression of MYC and BCL2 in R-CHOP treated diffuse large B cell lymphoma. J Clin Oncol. 2012. doi:10.1200/JCO.2011.41.0985
  11. Savage KJ, Johnson NA, Ben-Neriah S et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114:3533-3537. doi:http://dx.doi.org/10.1182/blood-2009-05-220095
  12. Alizadeh AA, Elsen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.  doi:10.1038/35000501
  13. Fernández-Rodríguez C, Bellosillo B, García-García M et al. MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma. Leukemia. 2014;10:2104-2106. doi:10.1038/leu.2014.184
  14. Maurer MJ, Micallef INM, Cerhan JR et al. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. J Clin Oncol. 2011;2912:1620-1626. doi:10.1200/JCO.2010.29.4413
  15. Jardin F, Molina TJ, Copie Bergman C et al. Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma. Leuk Lymphoma. 2013;54:1898-1907. doi:10.3109/10428194.2013.767456
  16. Cox MC, Di Napoli A, Scarpino S, Cavalieri E et al. Diffuse-Large-B-Cell Lymphoma Patients With Secreting IgM Monoclonal Component is A Very Poor Prognostic Subset. Blood. 2012;120:2659.
  17. Yi S, Liu W, Lyu R, Li Z, Xu Y, Sui W, Huang W, Wang T, Deng S, Liu H, Fu M, Zou D, Qiu L. Dose-intensive immunochemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of 29 newly diagnosed young patients with medium/high risk diffuse large B-cell lymphoma. Zhonghua Xue Ye Xue Za Zhi. 2014;35(6):546-650.  doi:10.3760/cma.j.issn.0253-2727.2014.06.016
  18. Magomedova A. Diffuse large lymphosarcoma of lymphoid organs: clinical forms, treatment. Dissertation. Russian Federation, Moscow; 2008. (In Russ.)
  19. Gavrilina O. The study of B-cell clonality and SOCS1 gene mutation status in patients with diffuse large cell lymphoma. [dissertation]. Moscow; 2015. (In Russ.) http://blood.ru/dc/gavrilina.pdf
  20. Gomyo H, Shimoyama M, Minagawa K, Yakushijin K, Urahama N, Okamura A., Yamamoto K, Ito M, Chihara K, Hayashi Y, Matsui T. Morphologic, flow cytometric and cytogenetic evaluation of bone marrow involvement inB-cell lymphoma. Haematologica. 2003;88(12):1358-1365.
  21. Kim S, Kim H, Kang H, Kim J, Eom H., Kim T, Yoon SS, Suh C, Lee D. Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large Bcell lymphoma: prognostic significance and relevance to histologic involvement. J Hematol Oncol. 2013;6:76.  doi:10.1186/1756-8722-6-76
  22. Merli M, Arcaini L, Boveri E, Rattotti S, Picone C, Passamonti F, Tenore A, Sozzani L, Lucioni M, Varettoni M, Rizzi S, Morello L, Ferretti V, Pascutto C, Paulli M, Lazzarino M. Assessment of bone marrow involvement in nonHodgkin's lymphomas: comparison betweenhistology and flow cytometry. Eur J Haematol. 2010;85(5):405-415.  doi:10.1111/j.1600-0609.2010.01503.x
  23. Talaulikar D, Shadbolt B, Dahlstrom JE, McDonald A. Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI). J Hematol Oncol. 2009;22(2):49.  doi:10.1186/1756-8722-2-49
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.